2021 market access prospects for Spain2021 will be the year when big market access changes – including the far wider use of health Share X2021 market access prospects for Spainhttps://pharmaphorum.com/views-analysis-market-access/2021-market-access-prospects-for-spain/
Nine for 2021: Addressing the pandemic legacyIn this second ‘Nine for 2021‘ article, IQVIA’s Sarah Rickwood looks at four issues which will directly impact Share XNine for 2021: Addressing the pandemic legacyhttps://pharmaphorum.com/views-analysis-sales-marketing/nine-for-2021-pandemic-legacy/
Novartis set to overcome $14 billion patent cliff say analystsNovartis’ pipeline is strong enough to overcome a $14 billion patent cliff as blockbuster drugs face generic competition Share XNovartis set to overcome $14 billion patent cliff say analystshttps://pharmaphorum.com/news/novartis-set-to-overcome-14-billion-patent-cliff-analyst/
FDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarNovartis/Genentech’s eye drug Lucentis could be the next big blockbuster to face competition from cheaper biosimilars after its Share XFDA begins review of Samsung Bioepis/Biogen’s Lucentis biosimilarhttps://pharmaphorum.com/news/novartis-lucentis-could-face-biosimilar-competition/
COVID-19 tests prop up Roche as US biosimilars bite in Q3Roche’s pharmaceutical revenues have been hit by falling sales in its pharma division in Q3 but a spike Share XCOVID-19 tests prop up Roche as US biosimilars bite in Q3https://pharmaphorum.com/news/us-biosimilars-bite-into-roches-pharma-revenues/
Amgen’s cancer biosimilars stay on US market as court battle with Roche endsAmgen has scored yet another home run in the US courts, this time seeing off a legal challenge Share XAmgen’s cancer biosimilars stay on US market as court battle with Roche endshttps://pharmaphorum.com/news/amgens-cancer-biosimilars-stay-on-us-market-as-court-battle-with-roche-ends/
Breaking policy and perceptual barriers: BiosimilarsExperts from Research Partnership analyse the company’s Therapy Watch data to identify how market access policy has impacted Share XBreaking policy and perceptual barriers: Biosimilarshttps://deep-dive.pharmaphorum.com/magazine/market-access-2020/breaking-policy-and-perceptual-barriers-biosimilars/
Deep Dive: Market Access – Breaking BarriersIn this issue of Deep Dive we look at the changing landscape for pharma market access and start Share XDeep Dive: Market Access – Breaking Barriershttps://pharmaphorum.com/views-analysis-market-access/deep-dive-market-access/
Merck & Co spin off could start a trend in big pharmaMerck & Co’s strategy to spin off its older drugs and biosimilars into a new stand-alone business will Share XMerck & Co spin off could start a trend in big pharmahttps://pharmaphorum.com/news/merck-cos-spin-off-closely-watched-by/
